Saad Mushabab Alqahtani

Dr. Saad Mushabab Alqahtani

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in COVID
Verified
Journal Article
Open access
PDF file
SASaad Mushabab Alqahtani
Saad Mushabab Alqahtani
MAMushary Saeed Alqahtani
Mushary Saeed Alqahtani
KAKhaled Abdulwahab Amer
Khaled Abdulwahab Amer
FRFASIH UR RAHMAN
FASIH UR RAHMAN
RARazan Mohammed AlMasoudi
Razan Mohammed AlMasoudi
YEYahya Elsharif
Yahya Elsharif
Background: Coronaviruses, including SARS-CoV-2, cause a range of respiratory and gastrointestinal illnesses, with COVID-19 becoming a global pandemic in 2020. Favipiravir, an antiviral drug, has shown promising results in reducing disease progression and improving recovery in COVID-19 patients. Methodology: This retrospective cohort study evaluated the efficacy, safety, and clinical outcomes of favipiravir in COVID-19 pneumonia patients admitted to the AFHSR. The analysis included patient characteristics, treatment responses, and laboratory parameters. Data were cleaned using Excel and analyzed with IBM SPSS version 29.0.0. Results: Our study included 297 COVID-19 pneumonia patients treated with favipiravir, with 129 (43.4%) females and 165 (55.6%) males with a mean age of 61.47 years. Comorbidities were present in 223 patients (75.1%), most commonly diabetes (N = 78, 33.6%) and hypertension (N = 72, 31.0%). Common symptoms were shortness of breath (N = 92, 31.0%), a cough (N = 86, 29.0%), and fever (N = 69, 23.3%). Complications occurred in 53 patients (17.8%), with acute kidney injury in 15 patients (5.1%). The overall mortality was 62 (20.9%), higher in those with comorbidities (75.7%, p = 0.017). Kaplan–Meier analysis showed worse survival for patients with comorbidities (p = 0.049) and smokers (p = 0.042). Elevated WBCs, LDH, AST, and CRP were linked to better survival (p < 0.05). Non-survivors had more severe respiratory impairment (FiO2, p = 0.035). Conclusions: Our study suggests favipiravir may help reduce ICU admissions and mortality in COVID-19 pneumonia patients, but outcomes are significantly influenced by age, comorbidities, and complications. This highlights the need for individualized treatment strategies. Further randomized controlled trials are essential to define favipiravir’s role in COVID-19 management.

26 June 2026 in Neurosciences
Verified
Journal Article
Open access
PDF file
AMAl-Amir Bassiouny Mohamed
Al-Amir Bassiouny Mohamed
MAMaeed Alkathiri
Maeed Alkathiri
SASaad Mushabab Alqahtani
Saad Mushabab Alqahtani
NANaif Hadi Ali
Naif Hadi Ali
SKSaima Kashif
Saima Kashif
ABAhmed Borai
Ahmed Borai
Objective: Migraine is a highly disabling neurological condition, and increasing attention has focused on a possible connection with patent foramen ovale (PFO). Methods: This single-center observational study enrolled 45 individuals from January to April 2024: 30 migraine patients with PFO (Group 1) and 15 migraine patients without PFO serving as controls (Group 2). All subjects underwent transthoracic echocardiography and completed standardized instruments including the Migraine Disability Assessment (MIDAS), Headache Impact Test (HIT-6), Migraine Symptom Severity Scale (MSSS), Allodynia Symptom Checklist (ASC-12), Visual Aura Rating Scale (VARS), and Migraine Treatment Optimization Questionnaire (mTOQ-6). Results: The participant's mean age was 37.3 ± 9 years. More than half experienced migraine with aura, a proportion notably greater among those with PFO. A positive family history, suboptimal response to therapy, and positional exacerbation were significantly associated with the PFO group. Fibrinogen concentrations and several migraine-related scores including MIDAS, HIT-6, MSSS, ASC-12, and mTOQ-6 differed significantly between groups. Conclusion: Migraine linked to PFO are more likely to have an aura, a stronger family patterns, worsening symptoms based on position, and overall, greater disability and increased severity of symptoms. These findings support an association between PFO and migraine characteristics and may have implications for clinical management.